<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666324</url>
  </required_header>
  <id_info>
    <org_study_id>Kalisz 2020-02</org_study_id>
    <nct_id>NCT04666324</nct_id>
  </id_info>
  <brief_title>Effects of Multilac Baby on Fecal Calprotectin Levels of Colicky Babies</brief_title>
  <official_title>Effects of Simethicone and Multilac Baby on Fecal Calprotectin Levels Infantile Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open trial with two parallel arms, assessing the effects of Simethicone and Multilac Baby on&#xD;
      crying behavior and fecal calprotectin levels in babies diagnosed for infantile colic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Babies aged 3 to 6 weeks will be diagnosed for infantile colic using the Wessel's criteria.&#xD;
      Study design will be open label with two parallel arms (Simethicone and Multilac Baby).&#xD;
      Multilac Baby is a synbiotic product containing probiotic bacteria (six lactobacilli and 3&#xD;
      bifidobacteria). Effects of treatments on crying behavior will be assessed by using parental&#xD;
      24h paper diaries. Fecal calprotectin values at the beginning and at the end of the study&#xD;
      will be evaluated using BÜHLMANN Quantum Blue® Calprotectin High Range (Schönenbuch,&#xD;
      Switzerland), a quantitative immunoassay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of days of crying</measure>
    <time_frame>Three weeks</time_frame>
    <description>Measurement of days of crying during last three weeks before enrollment and before the end of treatment. Treatment success will be determined by calculation the percentage of patients for whom the measurement will be reduced by the respective treatment by equal or more than 50 percent, compared to the value at the time of enrollment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of average duration of evening crying</measure>
    <time_frame>Three weeks</time_frame>
    <description>Measurement of average duration of evening crying during last three weeks before enrollment and before the end of treatment. Treatment success will be determined by calculation the percentage of patients for whom the measurement will be reduced by the respective treatment by equal or more than 50 percent, compared to the value at the time of enrollment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of fecal calprotectin values</measure>
    <time_frame>1-30 days</time_frame>
    <description>BÜHLMANN Quantum Blue® Calprotectin High Range (Schönenbuch, Switzerland). It is a quantitative determination of fecal calprotectin through a sandwich immunoassay. Treatment success will be determined by calculation the percentage of patients for whom the measurement will be reduced by the respective treatment by equal or more than 50 percent, compared to the value at the time of enrollment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infantile Colic</condition>
  <arm_group>
    <arm_group_label>Simethicone Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multilac Baby</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simethicone Solution</intervention_name>
    <description>Oral daily treatment for four weeks</description>
    <arm_group_label>Simethicone Solution</arm_group_label>
    <other_name>Control Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multilac Baby</intervention_name>
    <description>Oral daily treatment for four weeks</description>
    <arm_group_label>Multilac Baby</arm_group_label>
    <other_name>Treatment Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed for infantile colic according to Wessel's criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous treatment with probiotic or synbiotic&#xD;
&#xD;
          -  previous treatment with antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanna Krauss, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna i Krauss, Prof.</last_name>
    <phone>+48 88 33 89</phone>
    <phone_ext>788</phone_ext>
    <email>hjk12@pczta.fm</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacek Piatek, Prof.</last_name>
    <email>drpiatek@interia.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GP Clinic &quot;Panaceum&quot;</name>
      <address>
        <city>Brody</city>
        <zip>27-230</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marek Maciukajc, Dr.</last_name>
      <email>marek.maciukajc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jacek Piatek, Prof.</last_name>
      <email>drpiatek@interia.eu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GP Clinic &quot;Pro Familia&quot;</name>
      <address>
        <city>Koziegłowy</city>
        <zip>62028</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanna Krauss, Prof.</last_name>
      <email>hjk12@pczta.fm</email>
    </contact>
    <contact_backup>
      <last_name>Jacek Piatek, Prof.</last_name>
      <email>drpiatek@interia.eu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246756/</url>
    <description>Publication</description>
  </link>
  <results_reference>
    <citation>Piatek J, Krauss H, Ciechelska-Rybarczyk A, Bernatek M, Wojtyla-Buciora P, Sommermeyer H. In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters. Int J Environ Res Public Health. 2020 May 11;17(9). pii: E3332. doi: 10.3390/ijerph17093332.</citation>
    <PMID>32403297</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04666324/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

